EGFR and non-small cell lung carcinoma: EGFRm confer sensitivity to treatment with EGFR tyrosine kinase inhibitors (TKIs), with evidence that first-generation (erlotinib and gefitinib) and second-generation (afatinib and dacomitinib) EGFR TKIs have significantly improved progression-free survival (PFS) in treatment naïve, advanced EGFR positive NSCLC when compared with chemotherapy3–7.